Avantor Inc. Third Quarter Financial Results
Avantor, Inc. (NYSE: AVTR), a foremost global supplier of essential products and services tailored for the life sciences and advanced technology sectors, has revealed its financial results for the third quarter in a recent announcement.
Q3 2024 Highlights
The company's net sales settled at $1.71 billion, representing a minor decline of 0.3%. Organic sales saw a slightly higher decrease of 0.7%, while foreign currency adjustments yielded a beneficial impact of 0.4%.
Net income for the quarter fell to $57.8 million from $108.4 million a year earlier, with an adjusted EBITDA of $302.5 million, showcasing an adjusted EBITDA margin of 17.6%.
Income and Revenue Insights
The diluted profit per share based on Generally Accepted Accounting Principles (GAAP) was reported at $0.08, while the adjusted earnings per share stood at $0.26.
Cash flow from operations reached $244.8 million, with free cash flow reported at $204.0 million, showcasing a strong cash position for Avantor. The company maintains an adjusted net leverage of 3.8x as of the end of this quarter.
Segment Analysis: Performance by Division
Laboratory Solutions
In the Laboratory Solutions segment, sales recorded $1,171.5 million, marking a 1.1% increase from the same period last year, with growth of 0.6% on an organic basis. Adjusted operating income in this domain was $151.5 million, with a 12.9% margin.
Bioscience Production
The Bioscience Production segment reported net sales of $542.9 million, reflecting a decrease of 3.2%. The adjusted operating income in this sector was $138.1 million, demonstrating a solid adjusted operating income margin of 25.4%.
Future Outlook
As articulated by Michael Stubblefield, President and CEO of Avantor, the upcoming quarter is anticipated to realize mid to high single-digit growth in the bioprocessing business, spurred by ongoing improvements in order intake. The company’s strategic cost transformation initiatives are ahead of projections, positioning Avantor favorably for satisfying its full-year guidance.
Investor Relations Contact
For additional insights, investors can reach out to Christina Jones, Vice President, Investor Relations at Avantor. She can be contacted at +1 805-617-5297 or via email at Christina.Jones@avantorsciences.com.
Media Contact
For media inquiries, you may contact Eric Van Zanten, Head of External Communications at Avantor at +1 610-529-6219 or through email at Eric.Vanzanten@avantorsciences.com.
Frequently Asked Questions
1. What were Avantor's net sales for Q3 2024?
Avantor reported net sales of $1.71 billion for Q3 2024.
2. How did the adjusted EBITDA compare year-over-year?
The adjusted EBITDA was $302.5 million, compared to $171.6 million in the previous year.
3. What is Avantor's adjusted earnings per share for this quarter?
The adjusted earnings per share (EPS) is $0.26 for Q3 2024.
4. What are the segments where Avantor experienced growth?
The Laboratory Solutions segment saw an increase of 1.1%, while the Bioscience Production experienced a decrease of 3.2% in sales.
5. Who can be contacted for more information regarding Avantor's financial results?
Investors can contact Christina Jones at +1 805-617-5297 or Christina.Jones@avantorsciences.com.
